Shares of Intellicheck, Inc. (NASDAQ:IDN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.3750.
A number of brokerages recently commented on IDN. Weiss Ratings upgraded Intellicheck from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 5th. Wall Street Zen cut Intellicheck from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Zacks Research upgraded Intellicheck from a “hold” rating to a “strong-buy” rating in a research report on Friday, April 10th. DA Davidson restated a “buy” rating and issued a $7.50 price target on shares of Intellicheck in a research report on Wednesday, May 13th. Finally, Craig Hallum cut Intellicheck from a “buy” rating to a “hold” rating and set a $6.50 price target on the stock. in a research report on Wednesday, May 13th.
Get Our Latest Research Report on Intellicheck
Insider Transactions at Intellicheck
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Occudo Quantitative Strategies LP bought a new position in Intellicheck in the second quarter valued at about $65,000. Jump Financial LLC bought a new position in Intellicheck in the second quarter valued at about $66,000. PFG Investments LLC bought a new position in Intellicheck in the fourth quarter valued at about $70,000. JPMorgan Chase & Co. grew its position in Intellicheck by 21,267.7% in the second quarter. JPMorgan Chase & Co. now owns 13,889 shares of the company’s stock valued at $75,000 after acquiring an additional 13,824 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in Intellicheck in the second quarter valued at about $79,000. Institutional investors own 42.79% of the company’s stock.
Intellicheck Price Performance
IDN stock opened at $4.09 on Friday. Intellicheck has a fifty-two week low of $3.95 and a fifty-two week high of $9.08. The stock has a market capitalization of $82.82 million, a price-to-earnings ratio of 37.19 and a beta of 0.80. The business’s fifty day moving average price is $5.92 and its two-hundred day moving average price is $5.90.
Intellicheck (NASDAQ:IDN – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.03 EPS for the quarter, hitting analysts’ consensus estimates of $0.03. Intellicheck had a return on equity of 11.26% and a net margin of 9.56%.The company had revenue of $5.52 million for the quarter. Research analysts expect that Intellicheck will post 0.17 EPS for the current year.
Intellicheck Company Profile
Intellicheck, Inc is a provider of mobile identity verification and authentication solutions designed to help organizations verify credentials and combat fraud. The company’s technology leverages optical character recognition, machine learning, and biometric facial recognition to validate government‐issued IDs, passports, and other identity documents in real time. These solutions are deployed via on‐premises hardware or cloud‐based platforms, enabling clients to integrate identity checks directly into digital workflows and point‐of‐sale systems.
The firm’s flagship offerings include mobile credential scanning applications and software development kits (SDKs) that support Know Your Customer (KYC), Anti–Money Laundering (AML), age verification, and regulatory compliance across multiple industries.
Featured Stories
- Five stocks we like better than Intellicheck
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Intellicheck Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellicheck and related companies with MarketBeat.com's FREE daily email newsletter.
